{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Control+Subjects&page=37",
    "query": {
      "condition": "Healthy Control Subjects",
      "page": 37
    },
    "page_size": 10
  },
  "pagination": {
    "page": 37,
    "page_size": 10,
    "total_count": 1099,
    "total_pages": 110,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Control+Subjects&page=38&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Healthy+Control+Subjects&page=36&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T11:29:00.829Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03222401",
      "title": "Trial to Assess the Efficacy of F598 in Preventing an Experimental Urethral Infection With N. Gonorrhoeae in Healthy Males",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neisseria Gonorrhoeae"
      ],
      "interventions": [
        {
          "name": "1 mg/kg single infusion of F598",
          "type": "DRUG"
        },
        {
          "name": "3 mg/kg single infusion of F598",
          "type": "DRUG"
        },
        {
          "name": "10 mg/kg single infusion of F598",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alopexx Pharmaceuticals, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "35 Years",
        "sex": "MALE",
        "summary": "18 Years to 35 Years · Male only"
      },
      "enrollment_count": 10,
      "start_date": "2017-11-29",
      "completion_date": "2018-03-02",
      "has_results": false,
      "last_update_posted_date": "2019-02-08",
      "last_synced_at": "2026-11-13T11:29:00.829Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03222401"
    },
    {
      "nct_id": "NCT03345043",
      "title": "Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "VAL-339851",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "ModernaTX, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 156,
      "start_date": "2016-05-11",
      "completion_date": "2018-08-13",
      "has_results": false,
      "last_update_posted_date": "2021-01-11",
      "last_synced_at": "2026-11-13T11:29:00.829Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03345043"
    },
    {
      "nct_id": "NCT00979849",
      "title": "AZD8683 Single Ascending Dose Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "AZD8683",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "MALE",
        "summary": "18 Years to 45 Years · Male only"
      },
      "enrollment_count": 130,
      "start_date": "2009-10",
      "completion_date": "2010-01",
      "has_results": false,
      "last_update_posted_date": "2010-03-02",
      "last_synced_at": "2026-11-13T11:29:00.829Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00979849"
    },
    {
      "nct_id": "NCT03224325",
      "title": "A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Escalating Multiple Doses of TAK-831 in Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "TAK-831 Tablet T2",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "TAK-831 Suspension",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neurocrine Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 50,
      "start_date": "2017-07-21",
      "completion_date": "2018-09-09",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-11-13T11:29:00.829Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03224325"
    },
    {
      "nct_id": "NCT06221813",
      "title": "Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Nipah Virus Infection"
      ],
      "interventions": [
        {
          "name": "PHV02",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Lactated Ringer's",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Public Health Vaccines LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "59 Years",
        "sex": "ALL",
        "summary": "18 Years to 59 Years"
      },
      "enrollment_count": 120,
      "start_date": "2024-01-26",
      "completion_date": "2024-10-02",
      "has_results": false,
      "last_update_posted_date": "2025-06-08",
      "last_synced_at": "2026-11-13T11:29:00.829Z",
      "location_count": 3,
      "location_summary": "Anaheim, California • Hollywood, Florida • Salt Lake City, Utah",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06221813"
    },
    {
      "nct_id": "NCT02341508",
      "title": "A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Subjects"
      ],
      "interventions": [
        {
          "name": "0.5 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "1.0 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "3.0 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "10 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "20 mg/kg Lpathomab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline solution for intravenous infusion",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Lpath, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2015-09",
      "completion_date": "2016-03",
      "has_results": false,
      "last_update_posted_date": "2016-05-06",
      "last_synced_at": "2026-11-13T11:29:00.829Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02341508"
    },
    {
      "nct_id": "NCT01188317",
      "title": "A Study of Aleglitazar in Combination With Ibuprofen in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "aleglitazar",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "ibuprofen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "40 Years to 65 Years"
      },
      "enrollment_count": 44,
      "start_date": "2010-06",
      "completion_date": "2011-09",
      "has_results": false,
      "last_update_posted_date": "2012-05-22",
      "last_synced_at": "2026-11-13T11:29:00.829Z",
      "location_count": 1,
      "location_summary": "Omaha, Nebraska",
      "locations": [
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188317"
    },
    {
      "nct_id": "NCT01167868",
      "title": "A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "FosD",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "20 Years to 45 Years"
      },
      "enrollment_count": 56,
      "start_date": "2010-07",
      "completion_date": "2011-05",
      "has_results": false,
      "last_update_posted_date": "2013-02-07",
      "last_synced_at": "2026-11-13T11:29:00.829Z",
      "location_count": 1,
      "location_summary": "Glendale, California",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01167868"
    },
    {
      "nct_id": "NCT02655549",
      "title": "A Study of Anthrax Vaccines Px563L and RPA563 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anthrax"
      ],
      "interventions": [
        {
          "name": "Px563L, RPA563, or placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pfenex, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 54,
      "start_date": "2015-12",
      "completion_date": "2017-06",
      "has_results": false,
      "last_update_posted_date": "2017-07-11",
      "last_synced_at": "2026-11-13T11:29:00.829Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02655549"
    },
    {
      "nct_id": "NCT00291187",
      "title": "VEC-162 Study in Healthy Adult Volunteers in a Model of Insomnia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "20 mg VEC-162",
          "type": "DRUG"
        },
        {
          "name": "50 mg VEC-162",
          "type": "DRUG"
        },
        {
          "name": "100 mg VEC-162",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanda Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 411,
      "start_date": "2006-02",
      "completion_date": "2006-08",
      "has_results": true,
      "last_update_posted_date": "2014-10-15",
      "last_synced_at": "2026-11-13T11:29:00.829Z",
      "location_count": 19,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 16 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00291187"
    }
  ]
}